INVICTUS MD STRATEGIES CORP.
Invictus is pleased to announce that it has received approval from its Board of Directors to enter into the Joint Venture with CannAmerica and CBDC. Once the transaction is closed, the Joint Venture will mark the Company’s entry into the CBD market in the United States.
“This is another step towards building a long-term partnership with CannAmerica and CBDC to grow Invictus beyond Canada’s borders into the United States’ burgeoning CBD market,” said George E. Kveton, President and CEO of Invictus.
“We continue to make great progress with our partners to achieve the goals of creating this Joint Venture and the Joint Venture’s proposed acquisition of Z3 Sciences, LLC that was announced on January 16, 2019,” said Dan Anglin, CEO and Co-Founder of CANA.
Invictus has also granted 1,090,000 incentive stock options to certain eligible directors, employees and consultants of the Company. Each stock option has an exercise price of $1.20 and is exercisable into one common share of the Company. The options vest immediately and are exercisable over a period of five years. The stock options were granted subject to the terms and conditions of the Company’s Stock Option Plan.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
